In prostate cancer, HJURP increased the ubiquitination of cyclin-dependent kinase inhibitor one via the GSK3β/JNK signaling pathway, decreasing its stability and thereby promoting cell proliferation (Lai et al., 2021). Here, GSK3B is linked to prostate carcinoma.